The Ward
Ava was two years old. She had Epidermolysis Bullosa — a genetic condition in which the skin lacks the protein that binds its layers together. It blisters and shears at the slightest touch. A nurse changing her bandage could tear away tissue. Turning in her sleep could open wounds. The medical name is “mechanobullous disease.” The common name — “butterfly children” — comes from the only metaphor gentle enough: their skin is as fragile as a butterfly’s wing.
The children in the EB ward of the Iranian EB Home lie still because movement is pain. Epidermolysis Bullosa has no cure. It has management — a daily regime of wound care that, done correctly with the right materials, can prevent the infections that kill. The centerpiece of that regime is the bandage. Not any bandage — a specific one. Mepilex, manufactured by Mölnlycke Health Care in Sweden, is a soft silicone foam dressing that lifts from the wound bed without adhering to tissue. Unlike cotton gauze or standard adhesive bandages — which stick to the raw skin and tear newly formed cells away like a wax strip when removed — Mepilex separates cleanly. For an EB patient, this is not comfort. It is the difference between a wound that heals and a wound that becomes a portal for bacteria.
No generic equivalent exists in Iran. Domestic substitutes contain adhesives incompatible with EB wounds. When Mepilex disappeared from Iranian hospitals in 2018, families like Ava’s were left with two options: wash and reuse disposable Mepilex patches with alcohol — degrading the silicone with each cycle — or substitute cotton gauze that tears the skin it is meant to protect.
The Chain
The causal chain from sanctions policy to pediatric death in an Iranian hospital is six links long. Each link is documented. But the chain has two authors — and an honest accounting requires naming both from the start.
Link one: Designation. In 2018, the United States withdrew from the nuclear deal and reimposed comprehensive sanctions on Iran’s financial sector. Humanitarian goods — food, medicine, medical devices — were theoretically exempt.
Link two: Over-compliance. In 2014, BNP Paribas had been fined $8.9 billion for processing transactions that violated sanctions on Sudan, Iran, and Cuba — roughly a year of the bank’s earnings.1 The precedent created existential risk aversion across global banking. HSBC, Deutsche Bank, Standard Chartered, and every other major institution adopted a blanket policy: reject any transaction with an Iranian nexus. Compliance departments do not calculate the risk of processing a bandage invoice differently from the risk of processing a weapons payment. The risk is the same. The fine is the same.
Link three: Supply chain rupture. Mölnlycke Health Care — which had been selling Mepilex to Iran without incident — could no longer find a bank willing to process the payment. The company did not choose to embargo Iran. It was forced out by the collapse of the financial infrastructure between the company and the customer.
Link four: Clinical substitution. The Iranian EB Home exhausted its Mepilex stockpile. Families improvised — reusing disposable patches, substituting gauze, applying homemade wound covers. Each substitute increased the risk of infection.
Link five: Pathological consequence. Reused dressings lose their barrier properties. Cotton gauze tears tissue, creating new entry points for bacteria. Open wounds in immunocompromised children become infected with alarming speed.
Link six: Terminal outcome. Uncontrolled sepsis. Multi-organ failure. Death.
Ava did not survive. Her death from infection — reported across Iranian and international media — became the face of the bandage crisis.2
If your child had a condition like Ava’s, and the one bandage that could prevent fatal infection was manufactured in a Swedish factory but unreachable because no bank on earth would process the invoice — you would understand the precise nature of this cruelty. It is not a shortage. It is an architecture.
EB Deaths
Metric Figure EB patient deaths, May 2018–May 2019 15+ Total documented EB deaths from bandage shortage 30+
Zahra and Mohammad Mehdi Parvizi — siblings featured in the documentary Flight of Butterflies — survived. But without proper wound management, their fingers fused together — pseudosyndactyly, a condition in which open wounds between adjacent fingers heal into a single mass. Esophageal blistering caused severe malnutrition. Their survival is not a success story. It is a catalogue of preventable suffering documented on film.
But the chain has a shadow author. While butterfly children died for want of a Swedish bandage, the Islamic Republic was spending between $700 million and $1 billion annually on Hezbollah alone — a single proxy in a network spanning four countries.3 The regime that could not find a mechanism to import Mepilex had no difficulty routing billions through shell companies, hawala networks, and IRGC front operations to fund militias across the Middle East. The payment infrastructure for weapons never collapsed. Only the payment infrastructure for bandages did.
The regime’s response to Ava’s death was not medicine. It was litigation — a pattern called instrumentalized suffering, in which genuine victims are preserved as exhibits rather than treated as patients, because their propaganda value exceeds their medical value.
In July 2024, an Iranian court ruled the United States government liable for $6.785 billion in damages to EB patients.4 The ruling was a propaganda instrument — issued by a judiciary controlled by the same regime that could have allocated a fraction of its proxy warfare budget to procure the bandages through alternative channels. The regime had no interest in solving the crisis. It had an interest in preserving it — as evidence for the international stage, as leverage in sanctions negotiations, and as proof of the narrative that all suffering originates in Washington.
The Iron
Thalassemia Major is a genetic blood disorder that requires frequent blood transfusions to sustain life. Each transfusion deposits iron into the body — iron that accumulates in the heart, liver, and endocrine glands. Without chelation therapy — drugs that bind to excess iron and allow the body to excrete it — the iron kills. The heart fails. The timeline is measured in months to years.
The standard chelation drugs are Desferal (deferoxamine) and Exjade (deferasirox), manufactured principally by Novartis. Both are on the WHO’s List of Essential Medicines. Both are theoretically exempt from sanctions. Neither can be reliably imported into Iran, because the payment mechanism — Letters of Credit through SWIFT-connected banks — no longer exists.
Thalassemia: The Numbers
Metric Figure Deaths since 2018 1,100+ Deaths in a single year (2018–2019) 93 (cardiac failure from iron overload) Medication imported (year before May 2024) 12% of required volume Patients incompatible with domestic generic 35–40%
The domestic generic tells its own story. Iran manufactures a generic version of Desferal, but thirty-five to forty percent of thalassemia patients are medically incompatible with it — suffering severe injection site reactions, nausea, and critically, lower efficacy in iron removal that allows cardiac accumulation to continue. Younes Arab, head of the Iranian Thalassemia Association, has documented the incompatibility rate. For the patients in that thirty-five to forty percent, the domestic generic is not a substitute. It is a placebo with side effects, while iron accumulates in their hearts.
The mortality spike was immediate and measurable — a statistical deviation from baseline that correlates directly with the supply disruption.5 In most countries, a thalassemia diagnosis is manageable — regular transfusions and chelation therapy allow patients to live full lives. In Iran, the same diagnosis becomes a countdown, because the drug that would reset the clock is stuck at a compliance desk in Switzerland.
Meanwhile, state-connected entities were documented hoarding the chelation drugs that did enter the country. Albumin, intravenous immunoglobulin, and chelation agents were found warehoused in full stockrooms controlled by IRGC-linked distributors — while hospitals reported empty shelves.6 The regime did not merely fail to solve the shortage. It profited from it. Artificial scarcity inflates prices, and the entities controlling supply are the same entities that answer to the Revolutionary Guards, not the Health Ministry. The thalassemia patients who died of iron overload were killed by two systems — one that blocked the drugs at the border and one that hoarded them on the other side.
The Factor
Hemophilia patients require Factor VIII and Factor IX concentrates — clotting proteins derived from human plasma — to prevent internal bleeding. Without prophylactic treatment, minor injuries produce uncontrolled hemorrhaging. Repeated bleeding into joints — hemarthrosis — destroys cartilage and causes permanent disability.
Iran has been effectively excluded from the global plasma fractionation market. Six hemophilia patients died in a six-month period leading to September 2024, explicitly linked to a Factor IX shortage.7 Beyond mortality, the shortage created an epidemic of preventable joint destruction — hundreds of young adults rendered permanently disabled because the prophylactic treatment that would have protected their joints could not be obtained in sufficient quantities.
The hemophilia deaths are smaller in number than the thalassemia toll. They are not smaller in meaning. Each represents a person who died from the absence of a product that exists in abundance elsewhere in the world — a product whose import is theoretically legal and practically impossible.
The regime’s spending priorities make the deaths obscene rather than merely tragic. Iran’s ballistic missile program — the one the regime refused to include in any negotiation — costs an estimated $1-2 billion annually. The IRGC’s economic empire, controlled through Khatam al-Anbiya and the Setad conglomerate, manages assets worth tens of billions. The entire annual cost of importing chelation drugs, clotting factor, and EB bandages for every affected patient in Iran would amount to a rounding error in the IRGC’s budget. The regime chose missiles over medicine — not once, as an emergency decision, but year after year, as policy.
The Street
At the height of the sanctions crisis, essential cancer drugs vanished from Iranian hospitals — treatments that in any other country would be on the shelf, paid for, and administered without a bureaucratic obstacle between the patient and the cure.
“Dual-use” goods restrictions compound the pharmaceutical shortage. Replacement parts for linear accelerators — the machines that deliver radiation therapy — are classified as potential dual-use technology and blocked from import. Hospitals operate with aging equipment, delayed maintenance, and improvised repairs that increase the risk of malfunction mid-treatment. Cancer patients wait weeks for a radiation slot on a machine that should have been serviced months ago.
The Oncology Crisis
Indicator Figure Essential cancer drugs in short supply or unavailable 70% Increase in cancer mortality (sanctioned regions) 50% Source of substitute drugs Nasser Khosrow Street (black market)
The black market for medicine operates on Nasser Khosrow Street in central Tehran — a parallel pharmaceutical infrastructure born from the failure of the legal one. Drug prices — already inflated by the removal of the subsidized exchange rate for importers — are multiplied by currency devaluation and scarcity premiums. Families sell land and livestock for a single course of chemotherapy. The drugs they purchase may be counterfeit — improperly stored medications with broken cold chains, or outright fakes. A pharmacist documented patients paying hundreds of dollars for counterfeit Zavicefta, an antibiotic that, when fake, delivers nothing except false hope and a depleted bank account.
Iran International investigated the case of a young art student whose sister was dying of leukemia. The family exhausted every resource searching for the German-made chemotherapy drug Endoxan — first through legitimate channels, then through the black market. The drug was unavailable at any price. The sister died.
The black market itself operates in the regime’s shadow. The IRGC controls Iran’s “invisible jetties” — unauthorized ports outside government customs — where smuggled goods enter without quality controls, temperature regulation, or pharmaceutical safety standards.6 Drugs arriving through these channels may be degraded, counterfeit, or expired. The regime that failed to maintain legal import channels built an illegal one — and profited from the markup. The families buying medicine on Nasser Khosrow Street are paying inflated prices into a distribution chain that terminates, in many cases, at IRGC-connected wholesalers. The same organization that funds Hezbollah runs the medicine black market.
And in a detail that captures the regime’s priorities with forensic precision: pharmacies that fail to enforce the mandatory hijab dress code for employees and customers face punitive reductions in their drug quotas. The state conditions medical access on ideological compliance — rationing medicine as a tool of social control. A pharmacy owner must choose between enforcing the regime’s gender apartheid and receiving the drugs her patients need to survive.
The Channel
The mechanism is what compliance attorneys call a “paper exemption” — a legal carve-out designed to satisfy policy debates rather than move medicine across borders. Three humanitarian channels exist on paper. None functions at the scale required to prevent the deaths documented above.
The European Union created INSTEX — the Instrument in Support of Trade Exchanges — in 2019 as a barter mechanism to facilitate humanitarian trade outside the US financial system. In its entire operational life, INSTEX processed one transaction — a single shipment of medical goods. European companies refused to use it because their business exposure to the American market dwarfed any potential Iranian trade. INSTEX was dissolved in 2023, having proved only that US secondary sanctions exercise veto power over European sovereignty.
The Swiss Humanitarian Trade Arrangement, launched in 2020, processed €2.3 million in cancer and transplant drugs in its pilot transaction — against an annual medical import need exceeding $2.5 billion. The structural flaw is built into the design: the arrangement requires Iranian pharmaceutical companies to provide exhaustive data on their downstream distributors to the US Treasury. Many firms refuse — either because Iranian law prohibits the disclosure, or because they fear the data will be used to target them in future sanctions rounds. The SHTA remains technically operational and practically dormant.
The OFAC licensing system received thirty-one medical license applications in the first quarter of 2024 and issued twelve.8 General License 8 theoretically authorizes humanitarian trade, but banks demand specific licenses for every individual transaction. The result is a double bottleneck — each gate takes months to pass, and cancer patients have weeks.
The “enhanced due diligence” standard crystallizes the impossibility. US law requires verifying the “ultimate beneficiary” of every product. In Iran — where the state administers the hospital system — proving that a carton of bandages will never pass through the hands of a sanctioned entity is, as compliance attorneys describe it, “statistically and logistically impossible.” The standard does not filter humanitarian goods through the blockade. It is the blockade.
But the regime bears its own responsibility for the channel failures. The IRGC’s penetration of Iran’s pharmaceutical distribution network — the same invisible jetties, the same front companies, the same parallel import system — is precisely what makes the “ultimate beneficiary” standard impossible to satisfy. Western compliance officers cannot verify that a shipment of Desferal will reach a thalassemia ward rather than an IRGC warehouse because the regime has deliberately blurred the line between legitimate medical infrastructure and its own economic apparatus. The regime that demands humanitarian exemptions has built the system that makes them unverifiable.
The Honest Ledger
The humanitarian crisis has two authors. An honest accounting demands naming both — not one in the body and the other in a footnote.
The sanctions architecture is broken. The humanitarian exemption exists in law but not in practice. Over-compliance by global banks has created a de facto medical embargo that kills the most vulnerable patients — children, cancer patients, people with genetic blood disorders — while leaving the regime’s weapons procurement and proxy funding pipelines intact. The channels designed to prevent this outcome have failed comprehensively. This is a policy failure, and the United States bears responsibility for a system that exempts medicine in theory and blocks it in practice.
The Islamic Republic is the other author. The regime hoards imported medicine through IRGC-connected distributors. It operates smuggling ports where drugs arrive without safety controls. It conditions pharmacy quotas on hijab enforcement. It spends billions annually on proxy warfare and ballistic missiles while its butterfly children die for want of a bandage that costs a few dollars. It uses the suffering as propaganda — filing lawsuits for billions while allocating nothing from its own military budget to solve the crisis. And it has deliberately entangled its security apparatus with the civilian medical supply chain, making the humanitarian exemptions it demands structurally impossible to verify.
GAMAAN survey data shows that over eighty percent of Iranians blame domestic corruption for their economic misery. They are not wrong. But the population is caught between two systems of extraction — one that blocks medicine at the border and one that weaponizes scarcity on the other side. The butterfly children, the thalassemia patients, the hemophilia patients, the cancer patients — they are not casualties of one policy or one regime. They are ground between both.
The question is not which system is more to blame. The question is why the debate always centers on the sanctions — which can be reformed — rather than on the regime — which has demonstrated, across four decades, that it will sacrifice any number of its own citizens to preserve its military apparatus, its proxy network, and its grip on power.
Ava was two years old. The bandage cost four dollars.
This article is part of The Sanctions Paradox. For the maritime smuggling operation that moves Iranian oil past sanctions, see The Ghost Fleet. For how sanctions destroyed Iran’s middle class, see The Shrinking Sofreh.
Footnotes
-
US Department of Justice, “BNP Paribas Agrees to Plead Guilty and to Pay $8.9 Billion,” Press Release, June 2014 ↩
-
People’s Daily, “U.S. Sanctions Deprive Iran’s EB Children of Special Wound Dressings: NGO Chief,” March 2023; Human Rights Watch, “Iran: Sanctions Threatening Health,” October 2019 ↩
-
US State Department, Country Reports on Terrorism, 2017-2019; CSIS, “Hezbollah’s Finances,” 2018 ↩
-
Anadolu Agency, “Iranian Court Orders US to Pay $6.7 Billion in Damages to ‘Butterfly’ Patients,” July 2024 ↩
-
Iranian Thalassemia Association (Younes Arab), patient mortality documentation, 2019; OHCHR, “Iran: Over-Compliance with Unilateral Sanctions Affects Thalassemia Patients Say UN Experts,” February 2023 ↩
-
Asharq Al-Awsat, “IRGC-Linked Entities Control Medicine Distribution in Iran,” 2023; Iran International, reporting on invisible jetties and pharmaceutical hoarding, 2022-2024 ↩ ↩2
-
IranWire, “Iranians Face Shortage Crisis for Hemophilia Drugs,” September 2024 ↩
-
OFAC, Quarterly Report of Licensing Activities, Q1 2024 ↩